Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination

Cancer Research

Volumn 56, Issue 20, 1996, Pages 4735-4742

  Marais, Richard ^a   Spooner, Robert A ^a   Light, Yvonne ^a   Martin, Janet ^a   Springer, Caroline J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYPEPTIDASE G2; GLUTAMIC ACID DERIVATIVE; PRODRUG;

ARTICLE; CANCER CHEMOTHERAPY; COLON CARCINOMA; CONTROLLED STUDY; GENE THERAPY; HUMAN; HUMAN CELL; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL DESTRUCTION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; COS CELLS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GAMMA-GLUTAMYL HYDROLASE; GENE THERAPY; GENETIC VECTORS; GENTAMICINS; GLUTAMATES; HUMANS; MUTAGENESIS, SITE-DIRECTED; NITROGEN MUSTARD COMPOUNDS; OVARIAN NEOPLASMS; PRODRUGS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0029815716     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Calabresi, P., and Welch, A D. Cytotoxic drugs, hormones and radioactive isotopes. In: L S Goodman and A Gilman (eds ), Cytotoxic drugs, hormones, and radioactive isotopes, pp. 1345-1393. New York The Macmillan Company, 1994.
2. Zhang, W. W., Fujiwara, T., Grimm, E. A , and Roth, J A Advances in cancer gene therapy. Adv. Pharmacol , 12: 289-341, 1995.
3. Huber, B. E , Austin, E. A., Richards, C A , Davis, S. T., and Good, S. S. Metabolism of 5-fluorocytidine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase Proc Natl. Acad. Sci. USA, 91: 8302-8306, 1994.
4. Bridgewater, G , Springer, C. J , Knox, R., Minton, M., Michael, P , and Collins, M Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer, 31A 2362-2370, 1995
5. Niculescu-Duvaz, I , and Springer, C. J. Gene-directed enzyme prodrug therapy (GDEPT): choice of prodrugs. In: K. D Bagshawe (ed) Gene-directed Enzyme Prodrug Therapy (GDEPT). Choice of Prodrugs, in press Amsterdam: Elsevier Science B V , 1996.
6. Culver, K W , Ram, Z , Walbridge, S , Ishii, H., Oldfield, E H., and Blaese, M R. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science (Washington DC), 256: 1550-1552, 1992.
7. Vile, R G., and Hart, I R Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res., 53: 3860-3864, 1993.
8. Nabel, G J., Chang, A. E., Nabel, E. G., Plautz, G. E., Ensminger, W , Fox, B. A., Feigner, P., Shu, S , and Cho K. Immunotherapy for cancer by direct gene transfer into tumors Hum. Gene Ther , 5. 57-77, 1994.
9. O'Malley, B. W., Jr., Chen, S. H , Schwartz, M. R., and Woo, S. L. C. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model Cancer Res , 55: 1080-1085, 1995
10. Vile, R., Miller, N , Chernayovsky, Y., and Hart, I. A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transtriptionally targeted expression of the HSVtk or IL-2 genes. Gene Ther., 1: 307-316, 1994.
11. Hughes, B. W., Wells, A. H., Bebok, Z., Gadi, V. K., Garver, R I , Parker, W. B., and Sorscher, E J Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res., 55: 3339-3345, 1995.
12. Ido, A., Nakata, K , Kato, Y , Nakao, K., Fujita, M., Ishii, N , Tamaoki, T., Shiku, H., and Nagataki, S. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase under the control of human α-fetoprotein gene promoter. Cancer Res , 55: 3105-3109, 1995.
13. Trinh, Q. T , Austin, E. A , Murray, D M., Knick, V. C., and Huber, B. E Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res , 55: 4808-4812, 1995.
14. Tanaka, T , Kanai, F , Okabe, S., Yoshida, Y., Wakimoto, H., Hamada, H , Shiratori, Y., Lan, K. H., Ishitobi, M., and Omata, M Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res , 56: 1341-1345, 1996.
15. Moolten, F. L Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res., 46: 5276-5281, 1986.
16. Borelli, E., Heyman, R., Hsi, M., and Evans, R. M. Targeting of an inducible toxic phenotype in animal cell. Proc. Natl Acad. Sci. USA, 85: 7572-7576, 1988.
17. Moolten, F. L., and Wells, J M Curability of tumors bearing herpes virus thymidine kinase genes transferred by retroviral vectors J Natl. Cancer Inst., 82: 297-300, 1990.
18. Huber, B A , Richards, C A , and Krenitsky, T. A. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc. Natl. Acad. Sci., USA, 88: 8039-8043, 1991.
19. Caruso, M., Panis, Y , Gagandeep, S., Houssin, D., Salzmann, J. L., and Klatzmann, D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene Proc. Natl. Acad Sci USA, 90 7024-7028, 1993.
20. Oldfield, E. H., Ram, Z., Culver, K. W., Blaese, R. M , and DeVroom, H. L Gene therapy for the treatment of brain tumors using intra-tumoral transduction with thymidine kinase gene and intravenous ganciclovir. Hum. Gene Ther., 4: 39-69, 1993.
21. Barba, D., Hardin, J., Ray, J., and Gage, F H Thymidine kinase-mediated killing of rat brain tumors. J. Neurosurg , 79: 729-735, 1993
22. Vile, R. G , and Hart, I. R. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res., 53: 962-967, 1993.
23. Barba, D., Hardin, J., Sadelain, M., and Gage, F. H. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors Proc. Natl. Acad Sci. USA, 91: 4348-4352, 1994.
24. Chen, H , Boiziau, J , Parker, F., Mailliet, P., Commercon, A , Tocque, B., Le Pecq, J. B., Roques, B. P., and Garbay, C. Structure-activity relationships in a series of 5-[(2, 5-dihydroxybenzyl)amino] salicylate inhibitors of EGF-rcceptor-associated tyrosine kinase: importance of additional hydrophobic aromatic interactions. J Med Chem , 37: 845-859, 1994.
25. Sorscher, E J., Peng, S., Bebok, Z., Allan, P W., Bennett, L. L , and Parker, W. B. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther , 1: 233-238, 1994
26. Patterson, A. V., Zhang, H., Moghaddam, A., Bicknell, R., Talbot, D. C , Stratford, I J., and Harris, A. L. Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br. J. Cancer, 72: 669-675, 1995.
27. Mullen, C A., Kilstrup, M , and Blaese, R. M Transfer of the bacterial gene for cytosine deaminase to a mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system Proc Natl Acad. Sci. USA, 89, 33-37, 1992.
28. Austin, E. A., and Huber, B. E. A first step in the development of gene therapy for colorectal carcinoma cloning, sequencing and expression of Escherichia coli cytosine deaminase. Mol. Pharmacol , 43: 380-387, 1993.
29. Huber, B. E., Austin, E A., Good, V. C , Knick, V C., Tibbels, S., and Richards, C A In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res , 53, 4619-4626, 1993.
30. Mullen, C. A., Coale, M. M., Lowe, R., and Blaese, R. M. Tumor expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor Cancer Res., 54: 1503-1506, 1994
31. Harris, J D., Gutierrez, A A., Hurst, H C , Sikora, K , and Lemoine, N R Gene therapy for cancer using tumor-specific prodrug activation. Gene Ther , 1: 1-6, 1994
32. Chen, L., and Waxman, D J. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer development of a combined chemotherapy/cancer gene therapy strategy Cancer Res., 55 581-589, 1995.
33. Teicher, B A., and Frei, E., III. Development of alkylating agent resistant human tumor cell lines. Cancer Chemother Pharmacol., 21: 292-298, 1988
34. Frei, E., III, Teicher, B A , Holden, S A., Cathcart, K N S., and Wang, Y. Preclinical studies and clinical correlation of the effect of alkylating drugs. Cancer Res., 48: 6117-6423, 1988.
35. Bagshawe, K D. ADEPT and related concepts Cell Biophys., 24/25: 83-91, 1994
36. Springer, C. J., Dowell, R. L., Burke, P. J , Hadley, E , Davies, D H , Blakey, D. C , Melton, R. G , and Niculescu-Duvaz, I Optimization of alkylating agent prodrugs derived from phenol and aniline mustards a new clinical candidate prodrug (ZD2767) for ADEPT. J Med. Chem., 2 687-706, 1995
37. Springer, C. J., Bagshawe, K D , Sharma, S K , Searle, F., Boden, J A , Antoniw, P., Burke, P. J , Rogers, G. T , Sherwood, R F , and Melton, R. G. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur. J Cancer, 27: 1361-1366, 1991
38. Sharma, S. K , Boden, J. A , Springer, C J., Burke, P. J , and Bagshawe, K D. Antibody-directed prodrug therapy (ADEPT), a three-phase study in ovarian tumour xenografts. Cell Biophys., 24/25: 219-228, 1994.
39. Antoniw, P., Springer, C. J., Bagshawe, K. D , Searle, F. Melton, R. G., Rogers, G. T., Burke, P. J., and Sherwood, R. F. Disposition of the prodrug 4-[bis(2-chloroethyl)amino]benzoyl-L-glutamic acid and its active parent drug in mice Br. J. Cancer, 62: 909-914, 1990.
40. Sharma, S K , Bagshawe, K D , Springer, C. J., Burke, P. J., Rogers, G. T., Boden J A , Antoniw, P., Melton, R. G., and Sherwood, R. F Antibody-directed enzyme prodrug therapy (ADEPT): a three phase system. Disease Markers, 9: 225-231, 1991
41. Eccles, S., Court, W J., Box, G. A., Dean, C J , Melton, R G., and Springer, C. J. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185. Cancer Res., 54, 5171-5177, 1994
42. Springer, C J , Antoniw, P , Bagshawe, K. D., Searle, F., Bisset, G. M. F , and Jarman, M. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J. Med. Chem., 33, 677-681, 1990.
43. Springer, C J., Antoniw, P., Bagshawe, K. D., and Wilman, D. E V. Comparison of half-lives and cytotoxicity of N-mesyloxyethyl- and N-chloroethyl-4-amino benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT). Anticancer Drug Design, 6: 467-479, 1991
44. Springer, C. J. Aspects of antibody directed prodrug therapy (ADEPT). In: J. Menon (ed ), Current Topics in Medicinal Chemistry, pp. 93-100, India: Council of Scientific Research, 1993
45. Sambrook, I., Fritsch, E F., and Maniatis. T. Molecular Cloning: A Laboratory Manual, Ed. 2. Cold Spring Harbor, NY Cold Spring Harbor Laboratory, 1989.
46. Minton, N. P , Atkinson, T , and Sherwood, R. F. Molecular Cloning of the Pseudomonas carboxypeptidase G2 gene and its expression in Escherichia coli and Pseudomonas putida. J. Bacteriol , 156, 1222-1227, 1983
47. Marais, R , Light, Y., Paterson, H. F., and Marshall, C. J. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J., 14 3136-3145, 1995.
48. Kozak, M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell, 44: 283-292, 1986.
49. IUPAC-IUB. Commission on biochemical nomenclature A one-letter notation for amino acid sequences, tentative rules Biochem J , 113: 1-4, 1969.
50. Hill, C S., Marais, R , John, S , Wynne, J., Dalton, S., and Treisman, R. Functional analysis of a growth factor responsive transcription factor complex. Cell, 73: 395-406, 1993
51. Mizushima, S , and Nagata, S. pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res , 18 5322, 1990.
52. Patel, G., Nasmyth, K., and Jones, N A new method for the isolation of recombinant baculoviruses. Nucleic Acids Research, 20: 97-104, 1992.
53. Springer, C. J CMDA, an antineoplastic prodrug Drugs Future, 18: 212-215, 1993
54. Marais, R. M , Hsuan, J J., McGuigan, C., Wynne, J., and Treisman, R. Casein kinase II phosphorylation increases the rate of serum response factor-binding site exchange. EMBO J., 11: 97-105, 1992
55. Towbin, H , and Gordon, J Immunoblotting and dot immunobinding: current status and outlook J. Immunol. Methods, 72: 313-340, 1984.
56. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.
57. Minton, N. P , Atkinson, T., Bruton, C. J , and Sherwood, R. F The complete nucleotide sequence of the Pseudomonas gene coding for carboxypeptidase G2 Gene (Amst), 31, 31-38, 1984
58. Tom, B. H., Rutzky, L H., Jakstys, M. M , Oyasu, R , Kaye, C , and Kahan, B. D. Human colonic adenocarcinoma cells 1 Establishment and description of a new cell line In Vitro, 12: 180-181, 1976.
59. Noguchi, P , Wallace, R , Johnson, J , Earley, E. M., O'Brien, S , Ferrone, S., Pellegrino, M. A , Milstien, J., Needy, C., Browne, W., and Petricciani, J Characterization of the WIDR: a human colon carcinoma cell line. In Vitro, 15: 401-408, 1979.
60. Hill, B. T., Whelan, R D , Gibby, E. M , Sheer, D , Hosking, L K., Shellard, S A , and Rupniak, H. T Establishment and characterisation of three new human ovarian carcinoma cell lines and initial evaluation of their potential in experimental chemotherapy studies. Int. J Cancer, 39: 219-225, 1987.
61. Louie, K. G , Behrens, B. C., Kinsella, T J , Hamilton, T C , Grotzinger, K. R., McKoy, W M., Winker, M. A , and Ozols, R F Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by butathionine sulfoximine Cancer Res , 45: 2110-2115, 1985.
62. Bagshawe, K. D , Sharma, S K . Springer, C. J., and Antoniw, P. Antibody directed enzyme prodrug therapy: a pilot-scale clinical trial. Tumor Targeting, 1: 17-30, 1995.
63. Springer, C. J., Poon, G. K., Sharma, S. K., and Bigshawe, K. D. Analysis of antibody-enzyme conjugate clearance by investigation of prodrug and active drug in ADEPT clinical study. Cell Biophys., 24/25: 193-207, 1994
64. Mar, E C , Chiou, J F., Cheng, Y. C., and Huang, E. S. Inhibition of cellular DNA polymerase-α and human cytomegalovirus-induced DNA polymerase by the triphosphates of 9-(2-hydroxyethoxymethyl)guanine and 9-(1, 3-dihydroxy-2-propoxymethyl)guanine. J. Virol., 53: 776-780, 1985
65. Golumbek, P. T., Hamzeh, F. M., Jaffee, E. M , Levitsky, H., Leitman, P , and Pardoll, D. M. Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. J. Immunother., 12: 224-230, 1992.
66. Frei, E., III Curative cancer chemotherapy. Cancer Res., 45: 6532-6538, 1985.
67. Ram, Z., Culver, K. W., Walbridge, S., Blaese, R M., and Oldfield, E. H. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res., 53: 83-88, 1993
68. Freeman, S. M., Abboud, C. N., Whartenby, K. A., Packman, C. H , Koeplin, D S., Moolten, F. S., and Abraham, G. N. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res., 53: 5274-5283, 1993.
69. Chen, L., Waxman, D. J., Chen, D., and Kufe, D. W. Sensitization of human breast cancer cells to cyclophosphamide and ifosphamide by transfer of a liver cytochrome P-450 gene. Cancer Res , 56: 1331-1340, 1996.